ACE inhibitors used in about 30% of CHF cases: Keystone plan encourages ACEs, close patient contact.
ACE INHIBITOR USE FOR CONGESTIVE HEART FAILURE OCCURS IN ABOUT 30% of appropriate cases in the face of literature references on the treatment benefits. Despite general recognition of the value of angiotensin-converting enzyme inhibitors in congestive heart failure, the products remain underused, Merck-Medco VP-Clinical Education and Training David Angaran told an April 23 session of the Ohio Pharmaceutical Seminar sponsored by Ohio State Pharmacy College in Columbus.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth